Share on StockTwits

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) saw a large growth in short interest in June. As of June 13th, there was short interest totalling 20,674,858 shares, a growth of 38.1% from the May 30th total of 14,974,242 shares, Analyst Ratings Net reports. Based on an average trading volume of 3,849,010 shares, the days-to-cover ratio is presently 5.4 days. Approximately 6.3% of the company’s shares are short sold.

In other Valeant Pharmaceuticals Intl news, EVP Robert Roswell Chai-Onn sold 10,203 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $121.70, for a total value of $1,241,705.10. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Cantor Fitzgerald raised their price target on shares of Valeant Pharmaceuticals Intl to $209.00 in a research note on Monday, June 2nd. Separately, analysts at CIBC initiated coverage on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, May 21st. They set an “outperform” rating and a $160.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Friday, May 16th. They now have a $153.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals Intl currently has an average rating of “Buy” and a consensus price target of $150.90.

Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 126.00 on Monday. Valeant Pharmaceuticals Intl has a 52-week low of $88.01 and a 52-week high of $153.10. The stock’s 50-day moving average is $126.0 and its 200-day moving average is $130.4. The company’s market cap is $42.244 billion.

Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its quarterly earnings data on Thursday, May 8th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.04. The company had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the company posted $1.30 earnings per share. The company’s revenue for the quarter was up 76.6% on a year-over-year basis. Analysts expect that Valeant Pharmaceuticals Intl will post $8.73 EPS for the current fiscal year.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.